Durvalumab With Thoracic Radiation Therapy Without Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer (DART)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT03999710

Title field or adapter rule

{'original_value': 'Durvalumab With Thoracic Radiation Therapy Without Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer (DART)', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-11-01T01:03:03.793906+00:00

Published At

2026-10-28T00:00:00+00:00

Record Updated At

2026-10-28

Source Retrieved At

2026-11-01T01:03:02.902675+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Non Small Cell Lung Cancer", "Lung Cancer", "Nsclc", "NSCLC Stage II", "NSCLC, Stage III"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-28", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT03999710"

protocolSection.identificationModule.officialTitle

"Durvalumab With Thoracic Radiation Therapy Without Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer (DART)"

protocolSection.statusModule.overallStatus

"COMPLETED"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Non Small Cell Lung Cancer (protocolSection.conditionsModule.conditions)
• Lung Cancer (protocolSection.conditionsModule.conditions)
• Nsclc (protocolSection.conditionsModule.conditions)
• NSCLC Stage II (protocolSection.conditionsModule.conditions)
• NSCLC, Stage III (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Non-Small Cell Lung Cancer'], 'description': 'Treatment will consist of 60 Gy in 30 fractions to fields encompassing gross tumor and lymph nodes.', 'name': 'Radiation Therapy', 'type': 'RADIATION'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Non-Small Cell Lung Cancer'], 'description': 'A dose of 1500mg (for patients \\>30kg in weight) will be administered using an IV bag containing 0.9% (w/v) saline or 5% (w/v) dextrose, with a final durvalumab concentration ranging from 1 to 15 mg/mL, and delivered through an IV administration set with a 0.2- or 0.22- μm filter.', 'name': 'Durvalumab', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• Durvalumab (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.